ArticleAntimicrobial agents and chemotherapy2019
Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model.
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- National Cohort of Compassionate Use of Meropenem-Vaborbactam: No Benefit over Meropenem forAntibiotics (Basel, Switzerland) · 2024Article
- The burden of antibiotic resistance of the main microorganisms causing infections in humans - review of the literature.Journal of medicine and life · 2024Review
- Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance.Antibiotics (Basel, Switzerland) · 2023Review
- Antibiotic Therapy Strategies for Treating Gram-Negative Severe Infections in the Critically Ill: A Narrative Review.Antibiotics (Basel, Switzerland) · 2023Review
- New Drugs for the Treatment ofAntibiotics (Basel, Switzerland) · 2022Review
- Article
- The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections.The Journal of antimicrobial chemotherapy · 2021Review
- Is it time to move away from polymyxins?: evidence and alternatives.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Review
- An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.Infectious diseases and therapy · 2020Review
- Human-Simulated Antimicrobial Regimens in Animal Models: Transparency and Validation Are Imperative.Antimicrobial agents and chemotherapy · 2020Article
- The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.Expert opinion on pharmacotherapy · 2019Review
- Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections.Journal of clinical medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have evaluated the activity of meropenem-vaborbactam against clinical isolates of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.